Baxter International (BAX) Earning Somewhat Favorable Press Coverage, Analysis Finds
News headlines about Baxter International (NYSE:BAX) have been trending somewhat positive on Friday, according to Accern Sentiment. The research group rates the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Baxter International earned a daily sentiment score of 0.17 on Accern’s scale. Accern also gave news headlines about the medical instruments supplier an impact score of 46.1207020975465 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news headlines that may have effected Accern’s rankings:
- New Research on Hemophilia Treatment Market focuses on top players like Baxter International, Inc. , Octapharma AG … – Medgadget (blog) (medgadget.com)
- Daniel Loeb Beats S&P Index Through August – GuruFocus.com – GuruFocus.com (gurufocus.com)
- Medical Specialty Bags Market to Reach US$9,833.9 Million by 2025 Globally: Transparency Market Research (marketwatch.com)
- Global Non Medicated Pain Management Market 2017 Baxter International Inc, Boston Scientific Corporation, DJO … – Medgadget (blog) (medgadget.com)
Baxter International (BAX) traded down 0.56% during mid-day trading on Friday, hitting $63.96. 4,525,594 shares of the company were exchanged. The stock has a market cap of $34.85 billion, a P/E ratio of 38.81 and a beta of 0.66. Baxter International has a 12-month low of $43.13 and a 12-month high of $64.75. The company has a 50 day moving average of $61.50 and a 200 day moving average of $57.69.
Baxter International (NYSE:BAX) last issued its earnings results on Wednesday, July 26th. The medical instruments supplier reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.06. The company had revenue of $2.61 billion for the quarter, compared to analyst estimates of $2.59 billion. Baxter International had a net margin of 8.85% and a return on equity of 14.82%. The company’s revenue for the quarter was up .8% on a year-over-year basis. During the same quarter last year, the firm earned $0.46 EPS. On average, equities research analysts expect that Baxter International will post $2.39 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, October 2nd. Stockholders of record on Friday, September 1st will be paid a $0.16 dividend. This represents a $0.64 annualized dividend and a dividend yield of 1.00%. The ex-dividend date is Wednesday, August 30th. Baxter International’s dividend payout ratio (DPR) is presently 38.79%.
A number of brokerages have recently weighed in on BAX. Stifel Nicolaus upped their price target on shares of Baxter International from $58.00 to $61.00 and gave the stock a “hold” rating in a research note on Wednesday, May 31st. BMO Capital Markets raised shares of Baxter International from a “market perform” rating to an “outperform” rating and upped their price target for the stock from $55.00 to $70.00 in a research note on Tuesday, July 11th. They noted that the move was a valuation call. Cowen and Company reaffirmed a “market perform” rating and issued a $68.00 price target (up from $66.00) on shares of Baxter International in a research note on Thursday, July 27th. Royal Bank Of Canada reaffirmed a “hold” rating and issued a $60.00 price target on shares of Baxter International in a research note on Friday, September 1st. Finally, BidaskClub lowered shares of Baxter International from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. Baxter International currently has an average rating of “Buy” and a consensus target price of $65.31.
COPYRIGHT VIOLATION NOTICE: “Baxter International (BAX) Earning Somewhat Favorable Press Coverage, Analysis Finds” was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this report on another site, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this report can be viewed at https://www.dailypolitical.com/2017/09/15/baxter-international-bax-earning-somewhat-favorable-press-coverage-analysis-finds.html.
In other news, SVP Giuseppe Accogli sold 12,670 shares of the firm’s stock in a transaction dated Thursday, August 17th. The shares were sold at an average price of $60.96, for a total value of $772,363.20. Following the transaction, the senior vice president now owns 33,286 shares of the company’s stock, valued at approximately $2,029,114.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Carole J. Shapazian sold 4,020 shares of the firm’s stock in a transaction dated Thursday, August 24th. The shares were sold at an average price of $61.61, for a total transaction of $247,672.20. Following the completion of the transaction, the director now directly owns 13,868 shares in the company, valued at approximately $854,407.48. The disclosure for this sale can be found here. Insiders sold a total of 35,050 shares of company stock worth $2,158,587 in the last ninety days. Insiders own 0.05% of the company’s stock.
About Baxter International
Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.
Receive News & Ratings for Baxter International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.